Livideanu Cristina

Dermatologie

Hôpital Larrey Toulouse
Toulouse, France

257 Activités

0 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Mastocytose Mastocytose généralisée Psoriasis Mastocytose cutanée Maladies de la peau Ostéoporose Syndrome d'activation mastocytaire Anaphylaxie Urticaire

Collaborateurs

Paul Carle

Hôpital Larrey Toulouse, Toulouse, France

Konstantinou Maria Polina

Hôpital Larrey Toulouse, Toulouse, France

Lamant Laurence

Oncopole Toulouse, Toulouse, France

Hermine Olivier

Hôpital Necker Enfants Malades, Paris, France

Industries

Lilly

32 collaboration(s)

Dernière en 2023

B3TSI

29 collaboration(s)

Dernière en 2023

UCB

22 collaboration(s)

Dernière en 2023

Janssen

20 collaboration(s)

Dernière en 2023

Dernières activités

The prevalence of osteoporosis is low in adult cutaneous mastocytosis patients.

The journal of allergy and clinical immunology. In practice 27 février 2024

AMETHYST: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Essai Clinique (Biogen) 15 février 2024

Prevalence Of The KIT D816V Mutation In Peripheral Blood (PB) Of Patients With Evidence Of Systemic Mast Cell Activation (MCA): Results Of The Prospective, Multi-centered, Global PROSPECTOR Clinical Trial

Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2024 AAAAI Annual Meeting 01 février 2024

Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2024 AAAAI Annual Meeting 01 février 2024

Cladribine (2-CdA) improves cutaneous manifestations, DLQI and MC-QoL of patients with mastocytosis.

Journal of the American Academy of Dermatology 12 janvier 2024

Impact du guselkumab en vie réelle sur différents paramètres de la qualité de vie de patients atteints de psoriasis modéré à sévère : étude CASSIOPEE